Bedside Snapshot (ED/EMS/Prehospital)
  • Core dose: 3 mL via handheld inhaler (the "Green Whistle"); patient self-administers under supervision; max 6 mL/day, 15 mL/week
  • Onset/duration: Analgesia within 6-8 breaths; effects persist ~30 minutes after stopping inhalation; each 3 mL dose lasts approximately 25-30 minutes
  • Key danger: Nephrotoxicity at high cumulative doses (>2.5 MAC hours historically); avoid in pre-existing renal disease, diabetes mellitus; do NOT use on consecutive days; avoid with tetracyclines
  • Special: Non-opioid alternative for acute trauma pain; portable and disposable device; patient controls depth of analgesia; warn of potential headache, dizziness, and fruity smell; maintain adequate ventilation; contraindicated with known malignant hyperthermia susceptibility
đź’ˇ The "Green Whistle": Named for the distinctive green color of the Penthrox inhaler. Originally used as a general anesthetic in the 1960s-70s, now repurposed at low analgesic doses. Popular in Australian/New Zealand EMS since the 1970s; approved in UK/Ireland/EU for trauma pain.
Brand & Generic Names
  • Generic Name: Methoxyflurane
  • Brand Names: Penthrox, Penthrane (discontinued anesthetic formulation)
  • Common Nicknames: "Green Whistle," "Penthrane Whistle"
Medication Class

Volatile halogenated ether, inhaled analgesic (subanesthetic dose), general anesthetic (historic use)

Pharmacology

Mechanism of Action:

  • Positive allosteric modulator of GABAA and glycine receptors in the CNS
  • At subanesthetic concentrations, provides potent analgesia and sedation without loss of consciousness
  • Exact mechanism not fully defined; likely involves multiple molecular targets in brain and spinal cord
  • High lipid solubility allows rapid CNS penetration and persists in fat compartments, providing sustained analgesia

Pharmacokinetics:

  • Onset: Rapid—analgesia after 6-8 breaths (within 1-2 minutes)
  • Duration: Effects last approximately 30 minutes after cessation; may persist longer due to high lipid solubility
  • Metabolism: ~70% hepatically metabolized via O-demethylation to fluoride ions and dichloroacetic acid (DCAA)—metabolites responsible for historical nephrotoxicity at anesthetic doses
  • Elimination: Metabolites excreted renally; slow release from fat stores
  • MAC: 0.16% (extremely potent; analgesic doses are well below anesthetic threshold)
ℹ️ Key Property: Blood:Gas partition coefficient of 12 (high solubility) means slow induction/emergence as an anesthetic, but excellent for sustained low-dose analgesia.
Indications
  • Primary indication: Emergency relief of moderate to severe acute pain due to trauma
  • Prehospital analgesia (ambulance services, military field medicine)
  • Short painful procedures (wound care, dressing changes, fracture reduction, IUD insertion)
  • Labor analgesia (historic use)
  • Burns dressing changes
  • Alternative to nitrous oxide (Entonox) when contraindicated (chest injuries, pneumothorax)
💡 Prehospital Advantage: Unlike Entonox, methoxyflurane is safe in chest trauma/pneumothorax and doesn't require bulky cylinders—the Penthrox inhaler fits in a pocket.
Conditions Treated
  • Acute traumatic pain (fractures, dislocations, lacerations)
  • Procedural pain (minor surgeries, wound debridement)
  • Burns
  • Renal colic
  • Visceral pain (prehospital abdominal pain)
  • Musculoskeletal injuries
  • Gynecological procedures (IUD insertion/removal)
Dosing & Administration

Available Forms:

  • Penthrox inhaler: 3 mL single-use vial with handheld device
  • Activated charcoal chamber (AC chamber) clips to mouthpiece to absorb exhaled vapors

Dosing:

Patient Population Single Dose Maximum Daily Maximum Weekly
Adults 3 mL inhaled PRN 6 mL (two doses) 15 mL
Children ≥5 years 3 mL inhaled PRN (with supervision) 6 mL 15 mL

Administration Technique:

  • Patient holds device and breathes through mouthpiece, controlling depth of inhalation
  • Dilution hole can be covered intermittently for stronger effect
  • Use AC chamber to reduce environmental vapor exposure
  • Patient remains conscious and in control throughout
  • Must be administered under direct medical supervision
⚠️ Dosing Limits: Do NOT exceed 6 mL in 24 hours or 15 mL in 7 days. Do NOT use on consecutive days. Risk of nephrotoxicity increases with cumulative exposure.
Contraindications

Absolute Contraindications:

  • Known hypersensitivity to methoxyflurane or other fluorinated anesthetics
  • Personal or family history of malignant hyperthermia
  • Pre-existing renal impairment or nephropathy
  • Diabetes mellitus (increased nephrotoxicity risk)
  • Use within 5 days of prior methoxyflurane administration
  • Concurrent tetracycline antibiotics (synergistic nephrotoxicity)
  • Altered level of consciousness (patient cannot self-administer safely)

Relative Contraindications:

  • Hepatic impairment
  • Concurrent use of other potentially nephrotoxic agents
  • Patients taking enzyme-inducing drugs (may increase toxic metabolites)
  • Cardiovascular instability (though generally hemodynamically well-tolerated)
Adverse Effects

Common (at analgesic doses):

  • Headache
  • Dizziness, lightheadedness
  • Drowsiness, somnolence
  • Nausea
  • Euphoria or feeling of relaxation
  • Cough

Rare/Serious (typically at anesthetic doses):

  • Nephrotoxicity: High-output renal failure, nephrogenic diabetes insipidus (dose-dependent, seen historically with anesthetic use >2.5 MAC hours)
  • Hepatotoxicity: Rare, dose-dependent
  • Malignant hyperthermia: Potential trigger in susceptible individuals
  • Respiratory depression (at high concentrations)
  • Hypotension
  • Amnesia
ℹ️ Safety at Analgesic Doses: No significant nephrotoxicity has been reported with cumulative doses up to 6 mL (analgesic use). Toxicity was primarily seen at prolonged anesthetic exposure (>2.5 MAC hours).
Drug Interactions

Major Interactions:

  • Tetracyclines: Contraindicated—synergistic nephrotoxicity, potentially fatal
  • Other nephrotoxic drugs: NSAIDs, aminoglycosides, vancomycin—use caution, may potentiate renal effects
  • Enzyme inducers: Phenytoin, carbamazepine, rifampin—may increase formation of nephrotoxic metabolites

Moderate Interactions:

  • CNS depressants: Opioids, benzodiazepines, alcohol—additive sedation
  • Other volatile anesthetics: Additive effects if used concurrently
Clinical Pearls
đź’ˇ Non-Opioid Advantage: Methoxyflurane provides effective analgesia without opioid-related concerns (respiratory depression ceiling, constipation, dependence). Ideal for opioid-sparing prehospital protocols.
💡 Patient Self-Titration: The unique benefit of the Green Whistle is patient control—they inhale as needed and stop when pain is controlled, providing built-in dosing safety.
đź’ˇ Chest Trauma Advantage: Unlike nitrous oxide (Entonox), methoxyflurane does NOT expand air-filled spaces. Safe to use with pneumothorax, chest injuries, bowel obstruction.
💡 Pediatric Use: Approved for children ≥5 years old in many countries. The simple inhaler device is well-tolerated and easy for children to use with supervision.
đź’ˇ Occupational Exposure: Use the activated charcoal (AC) chamber attachment to minimize provider exposure. NIOSH recommends exposure limit of 2 ppm over 60 minutes.
Special Populations

Pregnancy (Category C in Australia):

  • May be used during labor for analgesia
  • Historically used in obstetrics without significant fetal effects at analgesic doses
  • Cross-references should be made to local guidelines

Pediatrics:

  • Approved for children ≥5 years old
  • Same dosing as adults (3 mL per dose)
  • Must be under direct supervision
  • Child must be able to follow instructions for self-administration

Geriatrics:

  • Use with caution in elderly patients
  • Consider reduced renal function—may increase toxicity risk
  • Monitor for excessive sedation

Renal Impairment:

  • Contraindicated in pre-existing renal disease

Hepatic Impairment:

  • Use with caution; monitor for adverse effects
References
  • 1. Jephcott C, Grummet J, Nguyen N, Spruyt O. A review of the safety and efficacy of inhaled methoxyflurane as an analgesic for outpatient procedures. Br J Anaesth. 2018;120(5):1040-1048.
  • 2. Grindlay J, Babl FE. Review article: Efficacy and safety of methoxyflurane analgesia in the emergency department and prehospital setting. Emerg Med Australas. 2009;21(1):4-11.
  • 3. McLennan JV. Is methoxyflurane a suitable battlefield analgesic? J R Army Med Corps. 2007;153(2):111-113.
  • 4. Babl FE, Jamison SR, Spicer M, Bernard S. Inhaled methoxyflurane as a prehospital analgesic in children. Emerg Med Australas. 2006;18(4):404-410.
  • 5. Mazze RI. Methoxyflurane revisited: tale of an anesthetic from cradle to grave. Anesthesiology. 2006;105(4):843-846.
  • 6. Australian Medicines Handbook. Methoxyflurane. 2025 Edition.
  • 7. National Prescribing Service (Australia). Methoxyflurane (Penthrox) for analgesia. NPS RADAR. 2010.
Back to Medication Index
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing and formatting this information. All content is reviewed for accuracy.